AQST - Aquestive Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
5.60
-0.30 (-5.08%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.90
Open5.90
Bid0.00 x 800
Ask0.00 x 800
Day's Range5.51 - 6.33
52 Week Range5.51 - 20.70
Volume120,758
Avg. Volume113,462
Market Cap139.86M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.96
Earnings DateMay 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.83
Trade prices are not sourced from all markets
  • PR Newswire8 days ago

    Aquestive Therapeutics to Announce First Quarter 2019 Financial Results and Recent Business Highlights on May 8, 2019

    WARREN, N.J., April 17, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that it will report results for the first quarter ended March 31, 2019 and provide a business update on Wednesday, May 8, 2019 before the market open. The Company will host an investment community conference call at 8:00 a.m. ET on Wednesday, May 8, 2019. There will also be a simultaneous, live webcast available on the Investors section of the Company's website at https://investors.aquestive.com/events-and-presentations.

  • Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application for Riluzole Oral Film for Treatment of ALS
    PR Newswire10 days ago

    Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application for Riluzole Oral Film for Treatment of ALS

    WARREN, N.J., April 16, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for the investigational product riluzole oral film (ROF), which the Company intends to market under the brand name Exservan™. ROF is a novel formulation of riluzole, which is used as an adjunctive therapy in the treatment of amyotrophic lateral sclerosis (ALS). The Company is exploring commercial opportunities for ROF in the U.S. and abroad.

  • PR Newswirelast month

    Aquestive Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference

    WARREN, N.J. , March 25, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic ...

  • Aquestive Therapeutics (AQST) Upgraded to Buy: Here's Why
    Zackslast month

    Aquestive Therapeutics (AQST) Upgraded to Buy: Here's Why

    Aquestive Therapeutics (AQST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • Associated Presslast month

    Aquestive Therapeutics: 4Q Earnings Snapshot

    On a per-share basis, the Warren, New Jersey-based company said it had a loss of 56 cents. The specialty pharmaceutical company posted revenue of $16.8 million in the period. For the year, the company ...

  • PR Newswirelast month

    Aquestive Therapeutics, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights

    - Secured U.S. Food and Drug Administration (FDA) approval and launched the first proprietary commercial product in its epilepsy franchise, SYMPAZAN™ (clobazam) Oral Film - Advancing two late stage CNS ...

  • Aquestive Therapeutics to Present at Oppenheimer's 29th Annual Healthcare Conference
    PR Newswire2 months ago

    Aquestive Therapeutics to Present at Oppenheimer's 29th Annual Healthcare Conference

    WARREN, N.J. , March 7, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic ...

  • Aquestive Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights on March 14, 2019
    PR Newswire2 months ago

    Aquestive Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights on March 14, 2019

    WARREN, N.J., Feb. 19, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that it will report results for the fourth quarter and full year ended December 31, 2018 and provide a business update on Thursday, March 14, 2019 before the market open. The Company will host an investment community conference call at 8:00 a.m. ET on Thursday, March 14, 2019. There will also be a simultaneous, live webcast available on the Investors section of the Company's website at https://investors.aquestive.com/events-and-presentations.

  • Aquestive Therapeutics to Present at 2019 BIO CEO & Investor Conference
    PR Newswire3 months ago

    Aquestive Therapeutics to Present at 2019 BIO CEO & Investor Conference

    WARREN, N.J., Feb. 8, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company, focused on developing and commercializing differentiated products to solve therapeutic problems today announced that management will present at the BIO CEO & Investor Conference to be held in New York, NY on February 11 and 12. Aquestive Therapeutics is a specialty pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. Aquestive is advancing a late-stage proprietary product pipeline to treat CNS conditions and provide alternatives to invasively-administered standard of care therapies.

  • Aquestive Therapeutics Provides Update Regarding Suboxone® Sublingual Film Litigation
    PR Newswire3 months ago

    Aquestive Therapeutics Provides Update Regarding Suboxone® Sublingual Film Litigation

    WARREN, N.J., Feb. 5, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company, focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that the U.S. Court of Appeals for the Federal Circuit denied a motion for a rehearing to reinstate the preliminary injunction against Dr. Reddy's Laboratory (DRL) regarding Suboxone® (buprenorphine/naloxone) Sublingual Film. This decision is not a judgement in the ongoing infringement cases against DRL and others regarding potential generic products entering the U.S. market. "This is one more step on the path to a final decision regarding the intellectual property infringement claims against DRL and others for potential generic Suboxone products.

  • Aquestive Therapeutics Provides Update on Licensee, Sunovion Pharmaceuticals Inc.'s Apomorphine Sublingual Film (APL-130277) New Drug Application
    PR Newswire3 months ago

    Aquestive Therapeutics Provides Update on Licensee, Sunovion Pharmaceuticals Inc.'s Apomorphine Sublingual Film (APL-130277) New Drug Application

    WARREN, N.J., Jan. 31, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic problems, learned today its licensee, Sunovion Pharmaceuticals Inc., received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) in response to the New Drug Application (NDA) for apomorphine sublingual film (APL-130277). "Additional treatment options for PD patients experiencing OFF episodes are important to the PD community.

  • Aquestive Therapeutics Granted Temporary Restraining Order (TRO) Against Alvogen
    PR Newswire3 months ago

    Aquestive Therapeutics Granted Temporary Restraining Order (TRO) Against Alvogen

    WARREN, N.J., Jan. 25, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company, focused on developing and commercializing differentiated products to solve therapeutic problems, today announced that the U.S. District Court for the District of New Jersey has granted a temporary restraining order (TRO) that enjoins Alvogen from initiating any launch activities related to its generic buprenorphine/naloxone sublingual film. This TRO will remain in place pending a hearing on the preliminary injunction (PI) motion previously filed by Aquestive and Indivior PLC (INDV.L).

  • Aquestive Therapeutics Appoints Gary H. Slatko, M.D. as Chief Medical Officer
    PR Newswire4 months ago

    Aquestive Therapeutics Appoints Gary H. Slatko, M.D. as Chief Medical Officer

    WARREN, N.J., Jan. 3, 2019 /PRNewswire/ -- Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to solve therapeutic problems, today announced the appointment of Gary H. Slatko as SVP, Chief Medical Officer (CMO). Dr. Slatko will lead clinical and medical affairs for the company, and is reporting to CEO Keith J. Kendall, effective January 2, 2019. "We are pleased to have Dr. Slatko join Aquestive and further our work in improving medications and outcomes for patients," said Keith J. Kendall, Chief Executive Officer of Aquestive Therapeutics.

  • Aquestive Therapeutics, Inc.’s (NASDAQ:AQST) Shift From Loss To Profit
    Simply Wall St.4 months ago

    Aquestive Therapeutics, Inc.’s (NASDAQ:AQST) Shift From Loss To Profit

    Aquestive Therapeutics, Inc.'s (NASDAQ:AQST): Aquestive Therapeutics, Inc., a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company’s loss has recently broadened Read More...

  • Aquestive Therapeutics Provides End of Year Business Update, Including Progress of its Proprietary CNS Assets, Financial and Legal Matters
    PR Newswire4 months ago

    Aquestive Therapeutics Provides End of Year Business Update, Including Progress of its Proprietary CNS Assets, Financial and Legal Matters

    WARREN, N.J., Dec. 20, 2018 /PRNewswire/ -- Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company pharmaceutical company focused on identifying, developing, and commercializing differentiated products to solve therapeutic problems, is reporting positive developments across its business. In November 2018, the company received approval from the U.S. Food and Drug Administration (FDA) for its first proprietary commercial product, Sympazan™, for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older. Aquestive's commercial team of 50+ experienced professionals have already completed thousands of interactions with local healthcare providers, payers that cover approximately 280 million lives, and pharmacists in markets nationwide.

  • Aquestive Therapeutics Schedules Business Update Conference Call on December 20, 2018
    PR Newswire4 months ago

    Aquestive Therapeutics Schedules Business Update Conference Call on December 20, 2018

    WARREN, N.J. , Dec. 18, 2018 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products ...

  • Aquestive Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
    PR Newswire5 months ago

    Aquestive Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference

    WARREN, N.J. , Dec. 7, 2018 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ: AQST ), a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products ...

  • Aquestive Therapeutics Announces Late-Breaking Findings of its Investigational Diazepam Buccal Film (DBF) Formulation in Adults with Epilepsy
    PR Newswire5 months ago

    Aquestive Therapeutics Announces Late-Breaking Findings of its Investigational Diazepam Buccal Film (DBF) Formulation in Adults with Epilepsy

    -- Studies show DBF, tentatively named Libervant™, was successfully administered and had similar bioavailability whether given during/immediately following a seizure or between seizures -- DBF, utilizing ...

  • Aquestive Therapeutics Launches SYMPAZAN™ (clobazam) Oral Film with Widespread U.S. Availability
    PR Newswire5 months ago

    Aquestive Therapeutics Launches SYMPAZAN™ (clobazam) Oral Film with Widespread U.S. Availability

    Establishes extensive Authorized Distributor Network to ensure easy access through retail pharmacies nationwide and mail order WARREN, N.J. , Nov. 29, 2018 /PRNewswire/ -- Aquestive Therapeutics, Inc. ...

  • GlobeNewswire5 months ago

    Market Trends Toward New Normal in Transcat, BioXcel Therapeutics, Youngevity International, Aquestive Therapeutics, TORM, and Transglobe Energy — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Benzinga5 months ago

    The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates

    Despite Friday's recovery, biotech stocks continued to hemorrhage last week following declines two weeks of declines. The earnings news flow from the sector is ebbing, but several conference presentations ...

  • Aquestive Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration (FDA) for Tadalafil Oral Film
    PR Newswire5 months ago

    Aquestive Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration (FDA) for Tadalafil Oral Film

    WARREN, N.J., Nov. 16, 2018 /PRNewswire/ -- Aquestive Therapeutics, Inc. (AQST) today announced it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) in regards to its New Drug Application (NDA) for tadalafil oral film (OF). Tadalafil is a PDE5 inhibitor currently marketed in tablet form for the treatment of erectile dysfunction and benign prostatic hyperplasia (BPH) under the brand name Cialis®, and for treatment of pulmonary arterial hypertension under the brand name Adcirca®. In the letter, the FDA requested limited additional data from healthy volunteers.

  • Associated Press6 months ago

    Aquestive Therapeutics: 3Q Earnings Snapshot

    On a per-share basis, the Warren, New Jersey-based company said it had a loss of 64 cents. Losses, adjusted for non-recurring costs, came to 49 cents per share. The specialty pharmaceutical company posted ...

  • Aquestive Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Highlights
    PR Newswire6 months ago

    Aquestive Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Highlights

    - Completed adult epilepsy monitoring study demonstrating that Libervant™ provides comparable bioavailability - Received FDA approval for SYMAPAZAN™ for the adjunctive treatment of seizures associated ...

  • Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval for SYMPAZAN™ (clobazam) Oral Film
    PR Newswire6 months ago

    Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval for SYMPAZAN™ (clobazam) Oral Film

    - SYMPAZAN is the first and only FDA-approved oral film formulation of clobazam, a benzodiazepine approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ...